Joshua Ryan Richter MD

Physician

10 E 102nd StNew York, NY 10029
Phone+1 212-241-6756

Dr. Richter is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Richter's full profile Already have an account?

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
New York Medical College at St Vincent's Hospital and Medical Center of New YorkResidency, Internal Medicine, 2005 - 2008
New York Medical CollegeClass of 2005

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2020 - Present
NJ State Medical License 2011 - 2027
NY State Medical License 2011 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite (with Beaker), Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017

Clinical Trials

Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma
UNKNOWN
PHASE1, PHASE2
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
COMPLETED
PHASE2
Myeloma-Developing Regimens Using Genomics (MyDRUG) Start of enrollment: 2019 Apr 01
COMPLETED
PHASE1, PHASE2
Roles: Contact

Publications & Presentations

PubMed

Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma.
Marina Samuel, Marcus S Flores, Jacob A Lowy, Michael F Rogers, Zachary M Avigan
Future Oncology. 2026-08-01
Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma.
Carlyn Rose Tan, Lucio Gordan, Joshua Richter, Rachel DiLeo, Prerna Mewawalla
Future Oncology. 2026-08-01
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
Adam D Cohen, Joshua Richter, Suzanne Trudel, Alexander Lesokhin, Jacob P Laubach
Nature Medicine. 2026-08-01

Abstracts/Posters

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma
Joshua R Richter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance
Joshua Richter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes
Joshua Richter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Hematologic Oncology Highlights: Dr. Faiman Shares Updates at JADPRO LiveNovember 6th, 2025
$Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma$
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple MyelomaJune 19th, 2025
How Bispecific Antibodies Could Make BCMA-Directed Therapy More AccessibleSeptember 20th, 2022